All Releases
 |
Intellipharmaceutics Announces 2011 Year End Results
Feb 8, 2012
|
30.8 KB |
|
| |
TORONTO, Feb. 8, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I), a pharmaceutical company specializing in the research, developme...
|
|
Intellipharmaceutics Appoints Vice President Business Development
Jan 30, 2012
|
14.2 KB |
|
| |
TORONTO, Jan. 30, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its United States subsidiary, Intellipharmaceutics Ltd...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the Biotech Showcase 2012
Jan 5, 2012
|
13.4 KB |
|
| |
TORONTO, Jan. 5, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Dr. Isa Odidi, CEO, will present a Company overview at ...
|
|
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement
Nov 25, 2011
|
14.8 KB |
|
| |
TORONTO, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf pros...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the 23rd Annual Piper Jaffray Healthcare Conference
Nov 23, 2011
|
13.4 KB |
|
| |
TORONTO, Nov. 23, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Fi...
|
|
Intellipharmaceutics' Manufacturing Facility Passes FDA cGMP and Pre-Approval Inspection
Nov 15, 2011
|
14.5 KB |
|
| |
TORONTO, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its Toronto-based oral solid dosage forms manufacturi...
|
|
FDA Accepts for Filing Intellipharmaceutics' ANDA for Generic Lamictal® XR™
Oct 31, 2011
|
14.5 KB |
|
| |
TORONTO, Oct. 31, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Lamictal® XR...
|
|
Intellipharmaceutics Announces Third Quarter 2011 Results
Oct 7, 2011
|
28.7 KB |
|
| |
TORONTO, Oct. 7, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the JMP Securities Healthcare Conference
Sep 26, 2011
|
14.2 KB |
|
| |
TORONTO, Sept. 26, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief F...
|
|
Intellipharmaceutics and Par Pharmaceutical Expand Development and Commercialization Agreement
Aug 18, 2011
|
14.4 KB |
|
| |
TORONTO, Aug. 18, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company and Par Pharmaceutical, Inc. (NYSE:PRX) ha...
|
|
Intellipharmaceutics Announces Second Quarter 2011 Results
Jul 5, 2011
|
29.4 KB |
|
| |
TORONTO, July 5, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended ...
|
|
Intellipharmaceutics Announces Settlement for Its Generic Version of Effexor XR(R)
Jun 21, 2011
|
14.4 KB |
|
| |
TORONTO, June 21, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced that Intellipharmaceutics and Wyeth LLC, a wholly owned subsidiary of Pfizer Inc., have settled the patent infringement litigation in the United States District Court for the Southern District of New York, relating to Intelliphar...
|
|
Intellipharmaceutics Provides Update on Activities Related to Generic Seroquel XR(R)
May 26, 2011
|
13.5 KB |
|
| |
TORONTO, May 26, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), today announced the following with regard to its generic drug commercialization activities.
AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited have filed suit for patent infringement against Intellipharmaceutics in the United States D...
|
|
FDA Accepts for Filing Intellipharmaceutics' ANDA for Generic Seroquel XR®
May 3, 2011
|
13.3 KB |
|
| |
TORONTO, May 3, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Seroquel XR® (quetiapine fumarate extended-release tablets). Seroquel XR® is an oral...
|
|
Intellipharmaceutics to Webcast Presentation at the Taglich Brothers 8th Annual Small Cap Equity Conference
Apr 27, 2011
|
13.6 KB |
|
| |
TORONTO, April 27, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its Vice President of Finance and Chief Financial Off...
|
|
Intellipharmaceutics Announces First Quarter 2011 Results
Apr 14, 2011
|
29.8 KB |
|
| |
TORONTO, April 14, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three month period ended ...
|
|
Intellipharmaceutics Provides Additional Update on Activities Related to 30mg Generic Version of Focalin XR(R)
Apr 5, 2011
|
14.6 KB |
|
| |
TORONTO, April 5, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced the following with regard to its generic drug commercialization activities.
Further to its press release issued on March 29, 2011, the Company has become aware that Celgene Corporation (Celgene), Novartis Pharmaceuticals Corp...
|
|
Intellipharmaceutics Files ANDA With FDA for Generic Seroquel XR(R)
Apr 4, 2011
|
14.0 KB |
|
| |
TORONTO, April 4, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic of Seroquel XR® (quetiapine fumarate extended-release tablets). Seroquel XR® is an oral psychotropi...
|
|
Intellipharmaceutics Provides Update on Activities Related to 30mg Generic Version of Focalin XR(R)
Mar 29, 2011
|
14.6 KB |
|
| |
TORONTO, March 29, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), today announced the following with regard to its generic drug commercialization activities.
The Company has become aware that Elan Corporation, plc and Elan Pharma International Ltd. have filed a Complaint against Intellipharmaceutics Corp...
|
|
Intellipharmaceutics Announces 2010 Year End Results
Feb 28, 2011
|
27.1 KB |
|
| |
TORONTO, Feb. 28, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled release and targeted release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 20...
|
|
|
